Host Epigenetic Alterations and Hepatitis B Virus-Associated Hepatocellular Carcinoma - CRCL-Epigénetique et épigénomique des carcinomes viro-induits Accéder directement au contenu
Article Dans Une Revue (Article De Synthèse) Journal of Clinical Medicine Année : 2021

Host Epigenetic Alterations and Hepatitis B Virus-Associated Hepatocellular Carcinoma

Résumé

Hepatocellular carcinoma (HCC) is the most frequent primary malignancy of the liver and a leading cause of cancer-related deaths worldwide. Although much progress has been made in HCC drug development in recent years, treatment options remain limited. The major cause of HCC is chronic hepatitis B virus (HBV) infection. Despite the existence of a vaccine, more than 250 million individuals are chronically infected by HBV. Current antiviral therapies can repress viral replication but to date there is no cure for chronic hepatitis B. Of note, inhibition of viral replication reduces but does not eliminate the risk of HCC development. HBV contributes to liver carcinogenesis by direct and indirect effects. This review summarizes the current knowledge of HBV-induced host epigenetic alterations and their association with HCC, with an emphasis on the interactions between HBV proteins and the host cell epigenetic machinery leading to modulation of gene expression.
Fichier principal
Vignette du fichier
jcm-10-01715.pdf (1.15 Mo) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-03851116 , version 1 (04-07-2023)

Identifiants

Citer

Mirjam Zeisel, Francesca Guerrieri, Massimo Levrero. Host Epigenetic Alterations and Hepatitis B Virus-Associated Hepatocellular Carcinoma. Journal of Clinical Medicine, 2021, 10 (8), pp.1715. ⟨10.3390/jcm10081715⟩. ⟨hal-03851116⟩
177 Consultations
13 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More